BRAF V600E Antibody

SKU: orb1822926

Description

The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8% of all solid tumours, including 45% of papillary thyroid carcinomas, 40-60% of melanomas, 5-15% of colorectal adenocarcinomas, 35% of serous low grade and borderline ovarian carcinomas, 1-3% of non-small cell lung cancers, and 5-7% of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100% of hairy cell leukaemia, 54% Erdheim-Chester disease, 38% of Langerhans cell histocytoses and 60% of pleomorphic xanthoastrocytomas.

Images & Validation

• Tested Applications: ELISA
• Dilution range: ELISA (Order BSA-free format for coating)
• Reactivity: Human

Key Properties

• Antibody Type: Primary Antibody
• Host: Mouse
• Clonality: Monoclonal
• Isotype: Mouse IgG, kappa
• Clone No.: V600E/1322
• Immunogen: An N-terminal KLH-conjugated peptide (amino acids 596-606, Cys-GLAT(E)KSRWSG) was used as the immunogen for the BRAF V600E antibody.
• Conjugation: Unconjugated

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Disclaimer: For research use only

SDS-PAGE analysis of purified, BSA-free BRAF V600E antibody (clone V600E/1322) as confirmation of integrity and purity.

Quick Database Links

UniProt

P15056